RESEARCH TRIANGLE PARK, N.C., May 23, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that mature Phase 2 results describing the positive impact of trilaciclib administered in combination with the TROP2 antibody-drug conjugate (ADC) sacituzumab govitecan (SG) on overall survival (OS) and tolerability compared to SG alone based on historical data from the ASCENT trial will be presented in a poster session during the upcoming 2024 American Society of Clinical Oncology (ASCO) Meeting.

北卡罗来纳州三角研究园，2024年5月23日（环球通讯社）--商业阶段肿瘤公司G1 Therapeutics，Inc.（纳斯达克：GTHX）今天宣布，根据ASCENT试验的历史数据，将在即将举行的2024年美国临床肿瘤学会（ASCO）会议上的海报会议上展示成熟的第二阶段结果，该结果描述了trilaciclib联合TROP2抗体-药物偶联物（ADC）sacituzumab-govitecan（SG）对总体生存率（OS）和耐受性的积极影响。

ASCO will be held May 31 to June 4, 2024, in Chicago, IL. A copy of the poster will be made available on the G1 Therapeutics website following the presentation here. The abstract was made available by ASCO today and includes the initial Phase 2 trial results originally provided by the Company in January 2024.

ASCO将于2024年5月31日至6月4日在伊利诺伊州芝加哥举行。海报副本将在G1 Therapeutics网站上发布。ASCO今天提供了摘要，其中包括该公司最初于2024年1月提供的第二阶段初步试验结果。

The poster that will be presented at ASCO will describe the mature results of the Phase 2 trial as an update to the initial results. Poster Presentation Details: Trilaciclib Combined with Sacituzumab Govitecan (SG) in Metastatic Triple Negative Breast Cancer (mTNBC): Updated Phase 2 Safety and Efficacy Results Seneviratne, L.

将在ASCO上发布的海报将描述第二阶段试验的成熟结果，作为初始结果的更新。海报展示细节：Trilaciclib联合Sacituzumab-Govitecan（SG）治疗转移性三阴性乳腺癌（mTNBC）：更新的2期安全性和有效性结果Seneviratne，L。

et al.Poster and abstract number 1091 Poster session: Breast Cancer-MetastaticSunday, June 2, 2024. 9:00 AM-12:00 PM CDT About G1 TherapeuticsG1 Therapeutics, Inc. is a commercial-stage oncology biopharmaceutical company whose mission is to develop and deliver next-generation therapies that improve the lives of those affected by cancer, including the Company’s first commercial product, COSELA® (trilaciclib).

海报和摘要1091海报会议：乳腺癌转移2024年6月2日，星期日。9： CDT关于G1 Therapeutics G1 Therapeutics，Inc.是一家商业阶段的肿瘤生物制药公司，其使命是开发和提供改善癌症患者生活的下一代疗法，包括该公司的第一款商业产品COSELA®（trilaciclib）。

The Company is also evaluating therapies in combination with cytotoxic therapies and/or immunotherapy in areas of high unmet need including triple-negative breast cancer and extensive stage sm.

该公司还在评估与细胞毒性疗法和/或免疫疗法相结合的疗法，以满足高度未满足的需求，包括三阴性乳腺癌和广泛期sm。